NAMS

In the past six months, NAMS stock has declined by 19.42%, and by 12.63% over the past year, trading near its 52-week low of $21.02 as of late September 2026. Key events include the European Commission granting marketing authorization for Ubeslo (obicetrapib monotherapy) and Evlarco (obicetrapib and ezetimibe fixed-dose combination) in September 2026, which had a muted stock reaction as it was largely anticipated. The stock has also been impacted by a broader biotech sell-off and challenging macroeconomic conditions, including surging bond yields and rising oil prices. A failed trial for a rival Lp(a)-lowering cardiovascular drug by Novartis in September 2026 contributed to a sector-wide sell-off for NAMS, despite analysts reiterating bullish ratings. Insider trading activity in September 2026 saw CEO Michael Davidson purchase shares, while other insiders sold shares in August and September. The company reported a Q2 loss and lagged revenue estimates in August 2026. The pivotal PREVAIL cardiovascular outcomes trial, with interim results expected in Q1 2027, remains a significant upcoming catalyst.